BRAF and neoplasm: A retrospective analysis revealed that NSCLC patients with BRAF V600E mutations (10 cases) had a lower tumor mutational burden (TMB) compared to non-V600E-mutant NSCLC patients (42 cases), and showed a lower ORR to immunotherapy (11% versus 23%, respectively).